Living Cell Technologies announced that it has received approval from the Auckland Hospital Research Review Committee to begin a Phase 2b clinical trial evaluating its lead product, NTCELL, as a potential treatment for Parkinson’s disease. Patient recruitment for the trial is now underway, the company said in a press release. NTCELL is an…
News
The free Hope Flies Health Series Webinar: Research Connecting Parkinson’s Disease and Mitochondrial Disease is scheduled for 1 p.m. Eastern Standard Time on Wednesday, April 6. The event is hosted by the Foundation for Mitochondrial Medicine (FMM) and partners Michael J. Fox Foundation (MJFF), Wilkins Parkinson’s Foundation and…
mPower, a Parkinson’s disease (PD) iPhone app developed by Sage Bionetworks and a team of neurologists at the University of Rochester Medical Center (URMC), marked the first year of its release by being highlighted in Apple Inc.’s “Loop You In” special product launch event on March 21, 2016.
Patients with rosacea may be at an increased risk of new-onset Parkinson’s disease, according to a Danish population study, “Exploring the Association Between Rosacea and Parkinson Disease: A Danish Nationwide Cohort Study,” published in JAMA Neurology. Rosacea is a common chronic inflammatory skin condition characterized…
News
3-D ‘Scaffolds’ Supporting Healthy Neurons Offer New Stem Cell-Treatment Approach for Parkinson’s
Rutgers and Stanford University researchers have developed 3-D “scaffolds,” or fibers, that can support healthy and high-functioning human neurons derived from adult stem cells, which can be transplanted to the brain to replace diseased neurons. The technology represents a possible new therapeutic strategy for numerous neurological conditions, including Parkinson’s and Alzheimer’s disease, amyotrophic lateral sclerosis, and multiple…
Multinational research-based biopharmaceutical company AbbVie‘s product DUOPA is a fresh approach to the administration of carbidopa and levodopa for the treatment of motor fluctuations that afflict people with advanced Parkinson’s disease. A researcher, in an exclusive interview with Parkinson’s News Today at the recent 10th World Congress on…
That the formation of alpha-synuclein aggregates, formed by misfolded forms of the protein, is somehow linked to Parkinson’s disease development is a fact few would dispute. Whether preventing the formation, or increasing the clearance of these protein masses, possibly by vaccination, as a viable approach to treatment is, however, a…
Cynapsus Therapeutics, currently conducting a pivotal Phase 3 clinical study of its sublingual formulation of apomorphine to treat “OFF” episodes in Parkinson’s disease (PD), is teaming up with the Michael J. Fox Foundation for Parkinson’s Research (MJFF) for a sub-study that will use wearable technology to gather and analyze…
The 10th World Congress on Controversies in Neurology (CONy), now taking place in Lisbon, Portugal, is hosting international experts in the field, and serving as a platform for the comparison of experimental clinical and basic data in a range of diseases. The congress also offers the opportunity for debate on unresolved scientific issues. Research into…
Emory University researchers, investigating the role of dopamine in the regulation of vocal learning through auditory feedback, observed that reducing this neurotransmitter in a specific brain area, the basal ganglia, considerably impairs learning. The study, in songbirds called Bengalese finches, further illuminate the role of dopamine in vocal behavior, and is relevant to Parkinson’s disease,…
Recent Posts
- First patient in US trial gets new off-the-shelf cell therapy for Parkinson’s
- When I became the unofficial offensive line in Parkinson’s quiet game
- The GPS of Theseus: Training the body’s navigation system with Parkinson’s
- New study highlights UTI risks in hospitalized Parkinson’s patients
- New exercise tips aim to help people with Parkinson’s stay active